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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.013Successful human pregnancy requires extensive invasion of maternal uterine tissues by the placenta.
Invasive extravillous trophoblasts derived from cytotrophoblast progenitors remodel maternal arterioles to
promote blood ﬂow to the placenta. In the pregnancy complication preeclampsia, extravillous trophoblasts
invasion and vessel remodeling are frequently impaired, likely contributing to fetal underperfusion and
maternal hypertension. We recently demonstrated in mouse trophoblast stem cells that hypoxia-inducible
factor-2 (HIF-2)-dependent Lim domain kinase 1 (LIMK1) expression regulates invasive trophoblast dif-
ferentiation bymodulating the trophoblast cytoskeleton. Interestingly, in humans, LIMK1 activity promotes
tumor cell invasion by modulating actin and microtubule integrity, as well as by modulating matrix met-
alloprotease processing. Here, we tested whether HIF-2a and LIMK1 expression patterns suggested similar
roles in the human placenta. We found that LIMK1 immunoreactivity mirrored HIF-2a in the human placenta
in utero and that LIMK1 activity regulated human cytotrophoblast cytoskeletal integrity, matrix
metallopeptidase-9 secretion, invasion, and differentiation in vitro. Importantly, we also found that
LIMK1 levels are frequently diminished in the preeclampsia setting in vivo. Our results therefore validate
the use of mouse trophoblast stem cells as a discovery platform for human placentation disorders and
suggest that LIMK1 activity helps promote human placental development in utero. (Am J Pathol 2014, 184:
3321e3331; http://dx.doi.org/10.1016/j.ajpath.2014.08.013)Supported by Eunice Kennedy Shriver National Institute of Child Health
and Human Development/NIH through cooperative agreement U54
HD055764-07 as part of the Specialized Cooperative Centers Program in
Reproduction and Infertility Research, as well as by R01 HD072455; the
California Institute for Regeneration Medicine grant TB1-01194 (A.M.R.);
and the 2214A-Abroad Research Fellowship for PhD students from the
Scientiﬁc and Technological Research Council of Turkey (G.U.).
Disclosures: None declared.Hypertensive disorders of pregnancy are a signiﬁcant cause of
maternal and neonatal morbidity worldwide.1,2 Preeclampsia
(PE), a poorly understood disorder, is characterized by
maternal hypertension, proteinuria, and edema, and affects
approximately 5% to 8% of all pregnancies.3 When untreated,
the syndrome can trigger maternal seizures (eclampsia) and
result in fetal underperfusion. The only deﬁnitive cure is
delivery of the placenta, thereby contributing to the epidemic
of preterm delivery.4 A leading theory regarding its etiology
implicates improper early placental development5 and inva-
sive trophoblast differentiation, followed bymaternal systemic
complications, via a two-stage process.6,7
Human placental development is characterized by the
remarkable invasion of maternal uterine structures by tropho-
blasts. The histological features of this interface are diagrammed
in Figure 1. Invasive extravillous trophoblasts (EVTs) derived
from column cytotrophoblast (cCTB) progenitors located at the
tips of anchoring villi (AV) migrate through the uterine paren-
chyma (interstitial invasion) in search of maternal spiralstigative Pathology.
.arterioles and veins (Figure 1A). This invasionpeaks around9 to
12 weeks of gestation.8 Via a process termed endovascular
invasion, EVTs then breach the spiral arterioles, where they
trigger the apoptotic death of resident endothelial and smooth
muscle cells9 and transdifferentiate into an endothelialized
trophoblast subtype that is capable of lining these vessels10
(Figure 1B). In the process, these high-resistance vessels are
remodeled into low-resistance/high-capacitance conduits
necessary for proper fetal perfusion and maternal hemody-
namics.11 Although the interactions with veins are largely
conﬁned to the inner surface of the uterus, EVTs migrate along
Zhou et almuch of the intrauterine course of the arterioles. Endovascular
invasion begins at the center of the placental bed, allowing
uterine arterial blood to ﬂow into the intervillous space by the
end of the ﬁrst trimester, where it bathes ﬂoating chorionic villi
covered by a layer of multinucleated syncytiotrophoblastsFigure 1 A and B: Schematic representation of the human maternale
vascular interface created by the placenta as a function of trophoblast inva-
sion. A: In the human placenta, the primary anatomical subunit is composed
of the chorionic villous, which can either be ﬂoating or anchoring. Floating
villi are composed of highly branched ﬁnger-like projections that are sur-
rounded by a layer of multinucleated SynT that perform the transport functions
of the placenta. B: Occasionally, the tips of villi attach to the uterus
(anchoring villous), triggering the expansion of a population of cytotropho-
blasts within cell columns that gives rise to invasive EVTs. Invading EVTs
migrate through uterine tissues in search of uterine arterioles that are
remodeled by them. During this process, EVTs breach the spiral arterioles,
triggering apoptotic death of existing endothelial and smooth muscle cells,
and line the spiral arterioles while transdifferentiating into an endothelialized
trophoblast cell type, expressing many cell surface markers characteristic of
endothelial cells. This allows for blood ﬂow from the arterioles into the
intervillous space. C: Model depicting induction of HIF activity in mouse
trophoblast stem (TS) cells by ECM composition or oxygen tension ([O2]). HIF
induction blocks TS cell differentiation along the SynT lineage and promotes
invasive trophoblast giant cell (TGC) differentiation via LIMK1 expression and
subsequent promotion of cytoskeletal integrity. BV, blood vessel.
3322(SynTs). SynTs perform essential transport functions of the
placenta, in addition to producingmultiple pregnancy hormones
in humans.12 Interestingly, only about one third of the uterine
spiral arteries are invaded by 18 weeks gestational age.13 In
normal pregnancies at term, however, most of the spiral arteries
are completely remodeled, indicating that the more lateral
arteries are progressively invaded throughout the second and
third trimesters.14,15
Formation of this vascular interface relies heavily on a pre-
cisely orchestrated set of interactions between EVT-expressed
adhesion molecules and the uterine extracellular matrix (ECM)
and vasculature, that are directly linked to trophoblast differ-
entiation.16e18 Interestingly, PE is associated with a dysregu-
lated pattern of adhesion molecule expression by EVTs that is
thought to be causally related to shallow placentation and
incomplete vascular transformation.19 For example, in PE,
EVTs fail to up-regulate expression of integrins avb3 and a1b1
on their cell surface.20 At a transcriptional level, EVTs express
much higher levels of Id2, a negative regulator of basic helix-
loop-helix family members that impairs differentiation.21,22
With regard to multinucleated SynTs that perform the trans-
port functions of the placenta, PE is associated with distur-
bances in their turnover,23,24 which may be due to diminished
cathepsin levels25 or reduced GCM1 expression,26 which leads
to parallel reductions in SynT differentiation and fusion.27
Thus, differentiation events within both the uterus and chori-
onic villi may be affected, suggesting that very early differen-
tiation events may be compromised.
Endovascular invasion by EVTs may also be compromised
in PE as a result of lower levels of vascular endothelial growth
(Vegf)-A and Vegfr-1, along with increased sFlt-1, a soluble
VEGF receptor that acts as a VEGF antagonist.28 Interestingly,
excess sFlt-1 produces a PE-like syndrome in rats.29 SynTs
exhibit increased staining for endoglin, a transforming growth
factor-b coreceptor, and forced expression of this molecule
also produces a PE-like syndrome in rats.30 By contrast,
human SynT expression of adrenomedullin (AM), a peptide
vasodilator, decreases in PE,31 and mice with reduced
maternal and/or fetal expression of this molecule also develop
signs of this syndrome.32 AM and the related AM2 can also
impact EVT invasion.33,34 Together, these ﬁndings led to the
concept that PE is a complex disorder associated with an
imbalance in angiogenic factors,35 suggesting inappropriate
activation of placental hypoxia responses that are strong acti-
vators of angiogenic pathways.
Hypoxia-inducible factor-1 (HIF-1) is a major regulator of
cellular hypoxia responses.36 A basic helix-loop-helix PAS
transcription factor composed of two subunits, HIF-1a andHIF-
1b/ARNT,37 this ubiquitous heterodimer is responsible for the
hypoxic induction of hundreds of genes by binding to hypoxia
response elements in their promoters or enhancers.38 We have
shown that HIF-1b/ARNT is critical for development, particu-
larly of the placenta, where oxygen tension regulates cell fate
decisions.39e41 In mice, Arnt/ placentas display a grossly
disrupted architecture as a result of reduced progenitor prolif-
eration and impaired vascularization. Furthermore, inactivationajp.amjpathol.org - The American Journal of Pathology
LIMK1 Regulates Human Placentationof the genes encoding the murine von Hippel-Lindau homolog,
as well as PHD2, conditions that produce constitutively active
HIF, also result in embryonic lethality that is due to impaired
placental vascularization,42,43 indicating that precise regulation
of HIF levels is critical for normal placentation. Interestingly,
HIF deﬁciency also impairs trophoblast stem cell (TSC)eECM
interactions,44 suggesting direct roles in invasion.
Importantly, oxygen tension can modulate human EVT
proliferation, differentiation, invasion, and ECM degrada-
tion.45e47 VEGF, VEGFR-2, and AM are induced by HIF
activity,48 and Gcm-1 is regulated by oxygen.49 Additionally,
oxygen tension can modulate human SynT differentiation.50
Furthermore, HIF deﬁciency in the mouse results in altered
trophoblast differentiation and cell surface integrin expression,
along with diminished VEGF expression,51 suggesting a
causal link. Finally, 2-methoxyestradiol, an estrogen metabo-
lite that can inhibit HIF activity,52 was shown to be reduced in
preeclamptic women, and its deﬁciency causes a PE-like
syndrome in mice.53 In sum, PE is associated with funda-
mental defects in trophoblast differentiation that negatively
impact endovascular invasion, SynT formation, and placental
development. Importantly, cellular hypoxia responses appear
to be involved in many of these pathways.
We recently described a novel role for HIF-dependent
signaling in the placenta. Speciﬁcally, we found that nonca-
nonical HIF signaling in mouse TSCs can regulate differen-
tiation via activation of the HIF-2especiﬁc cytoskeletal
regulatory protein, LIM domain kinase 1 (LIMK1).54 LIMK1
can modulate the actin cytoskeleton through coﬁlin phos-
phorylation,55 as well as the microtubule cytoskeleton through
p25 phosphorylation.56 Cytoskeletal integrity is critical for
trophoblast differentiation with invasive EVTs containing
robust actin and microtubule networks, whereas in multinu-
cleated SynTs, these are disrupted.54,57,58 Importantly, cyto-
skeleton disruption can redirect TSC fate along the SynT
lineage. Furthermore, LIMK1 activity promotes tumor cell
invasion and migration, both via cytoskeletal remodeling, as
well as matrix metalloproteinase (MMP) processing,56,59
suggesting similar roles in trophoblast invasion.
In mouse TSCs, HIF-1a and -2a are developmentally
induced in response to ECM-dependent cues downstream of
MAP2K1/2-dependent MAPK3/1 (Erk2/1) activity to repress
SynT formation54 (Figure 1C). In the absence of these cues,
hypoxic culture conditions can act through the same kinase
cascade to activate HIF-1a and, to a lesser extent, HIF-2a. It
has previously been demonstrated that HIF-2a levels are also
developmentally regulated in the human placenta.60 Similar to
mouse TSCs, invasive CTBs and their cCTBs progenitors
express high levels of this transcriptional regulator, whereas
SynTs do not. We wished to determine whether in the human
placenta trophoblast cytoskeletal integrity correlates with HIF-
2a activity spatially and temporally, and whether LIMK1
expression also plays important roles in human placental
development, as well as in PE pathogenesis. Our results sug-
gest such a role for LIMK1 activity in cytotrophoblast invasion
and differentiation, which is aberrant in PE.The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Antibodies and Limk-1 Inhibitor
Rat anti-human cytokeratin monoclonal antibody, 7D3, was
produced in the Fisher laboratory. Polyclonal rabbit antie
Limk-1, polyclonal rabbit antiephospho-MAP2K1/2, and
mouse monoclonal antiep-coﬁlin was purchased from Cell
Signaling Technology (Danvers, MA). Polyclonal rabbit anti-
HIF2a (NB100-22) was purchased from Novus Biologicals
(Littleton, CO). Polyclonal rabbit antiePAPP-A was from
DakoCytomation (Dako A/S, Glostrup, Denmark). Mouse
monoclonal antiea-actin was purchased from Sigma-Aldrich
(SaintLouis,MO).Mousemonoclonal anti-coﬁlinwas fromBD
Transduction Laboratories (San Jose, CA). Limk-1 inhibitor,
BMS-5, was purchased from Synkinase (Parkville, Australia).
Tissue Sources for Immunolocalization Experiments
Placentas were obtained from normal pregnant women and
patients with PE. We analyzed 10 control samples from pa-
tients with no evidence of PE, gestational hypertension, or a
medical history that suggested an increased risk of developing
PE. We analyzed ﬁve samples from patients with PE diag-
nosed according to the classic criteria originally recommended
byDr. Leon Chesley andmodiﬁed by the National Institutes of
Health61: no history of hypertension before pregnancy; in-
crease in diastolic pressure of 15mmHg or systolic pressure of
30 mm Hg compared with blood pressure obtained before 20
weeks of gestation; proteinuria0.5 g/24 hours or30mg/dL
(or 1þ on urine dipstick) in a catheterized specimen; hyper-
uricemia >5.5 mg/dL (or 1 SD greater than the normal mean
value before term); return to normal blood pressure and res-
olution of proteinuria by 12 weeks postpartum. Severe PE was
diagnosed according to the following criteria62: systolic
blood pressure of 160 mm Hg and/or diastolic pressure of
110 mm Hg; proteinuria of 5 g in a 24-hour period or 3þ
on a urine dipstick; presence of cerebral or visual disturbances;
36 weeks gestational age or less.
Immunolocalization
Placental tissues were processed for double indirect immuno-
localization as previously described.60 Tissues were ﬁxed in 3%
paraformaldehyde for 30 minutes, washed three times in PBS,
inﬁltrated with 5% to 15% sucrose followed by optimal cutting
temperature (OCT) compound medium, and frozen in liquid
nitrogen. Sections (5 mm) were prepared and incubated in a
mixture of anti-cytokeratin (to localize trophoblasts) and
another primary antibody for 2 hours. The sections were then
rinsed and incubated with the appropriate species-speciﬁc sec-
ondary antibodies conjugated to rhodamine or ﬂuorescein.
Samples were examined with a Leica epiﬂuorescence micro-
scope (Leica Microsystems, Buffalo Grove, IL). For immuno-
localization of antigens expressed by cultured cytotrophoblasts,
isolated cells were plated on coverslips coated with Matrigel3323
Figure 2 Immunoﬂuorescence microscopy-
based analysis of HIF-2a and a-tubulin immunore-
activity in the human placenta. Placentas (6-, 15-,
and 23-week-old) were stained with antibodies for
HIF-2a, a-tubulin, or cytokeratin (CK). The upper
row represents an assessment of expression patterns
in FV at 6 weeks, whereas the lower rows represent
staining patterns in AV across multiple gestational
ages. As seen, vCTB progenitors of SynT exhibit HIF-
2a, as well as a-tubulin, immunoreactivity, which is
nearly completely lost on syncytialization. This
pattern is maintained in the second trimester as well
(not shown). Note the lack of HIF-2a and a-tubulin
staining, with positive CK immunoreactivity, in the
SynT layer immediately surrounding vCTBs (arrows).
Additionally, CTBs within cell columns at 6 and 15
weeks express abundant nuclear HIF-2a immunore-
activity, as well as cytoplasmic a-tubulin immuno-
reactivity. Interestingly, by the end of the second
trimester (23 weeks), HIF-2a immunoreactivity is
more diffuse and less intense, although still greater
than negative control staining (Supplemental
Figure S1). CK staining demarcates all trophoblast
populations.
Zhou et al(Collaborative Biomedical Products, Bedford, MA) for various
periods of time, then ﬁxed in 3% paraformaldehyde for 5 mi-
nutes and permeabilized with cold methanol for another 5 mi-
nutes. Samples were stained and analyzed as described above.
Secondary antibodyealone negative control images are pro-
vided in Supplemental Figure S1.
Cytotrophoblast Isolation and Culture
Cytotrophoblasts were isolated from chorionic villi of 6- to
24-week human placentas by routine procedures established in
our laboratory.60 Brieﬂy, the placentas were obtained immedi-
ately after elective pregnancy terminations. After a series of
collagenase and trypsin digestions, cytotrophoblasts were
separated from contaminating cell types on Percoll gradients.
Puriﬁed cells were used immediately or cultured in serum-free
high-glucose medium on Matrigel-coated substrates for the
times indicated.
Cell Extraction and Immunoblotting
Freshly isolated cytotrophoblasts or cytotrophoblasts cultured
on Matrigel-coated wells were washed twice with PBS and
extracted with 200 mL of lysis buffer [50 mmol/L Tris buffer
(pH 7.6), containing 1%Nonidet P-40, 0.1% SDS, 120 mmol/3324LNaCl, plus EDTA-free protease inhibitor]. Cell extracts were
centrifuged at 12,000  g for 10 minutes to remove insoluble
materials. Samples containing equal amounts of protein were
mixed with SDS sample buffer and separated by SDS-
polyacrylamide gel electrophoresis. After the proteins were
transferred to nitrocellulose, the membranes were incubated
ﬁrst with the primary antibody, then with peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch
Laboratories, West Grove, PA). Immune complexes were
visualized using enhanced chemiluminescence and Hyperﬁlm
(GE Healthcare, Pittsburgh, PA).Invasion Assay
Invasion assays were conducted as described previously.28
Brieﬂy, isolated cytotrophoblasts (0.25  106) were plated
on Transwell inserts (6.5 mm; Costar, Cambridge, MA)
containing polycarbonate ﬁlters (pore size, 8 mm) that had
been coated with Matrigel. Culture medium containing either
1 mL/mL 10 mmol/L BMS-5 or 1 mL/mL dimethyl sulfoxide
was added. After 48 hours, the cultures were stained with the
7D3 antibody, which speciﬁcally reacts with human cyto-
keratin, to visualize the cytotrophoblasts. The ﬁlters were cut
from the supports and mounted, upper surface facing down,
on slides. The number of cytokeratin-positive cells and cellajp.amjpathol.org - The American Journal of Pathology
Figure 3 Expression pattern of LIMK1 within AV during the ﬁrst two
trimesters of human placental development. Immunoﬂuorescence
microscopy-based analysis of LIMK1 expression was undertaken in tissue
sections of human placental segments containing AV at weeks 6, 9, 15, and
23. CK staining served as a marker of all placental cells. Nontrophoblasts do
not exhibit immunoreactivity for CK. DAPI was used to stain nuclei. vCTB,
SynT, and cCTBs are indicated.
LIMK1 Regulates Human Placentationprocesses on the lower surface of the ﬁlter was counted. Each
experimental condition was tested in triplicate, and the entire
assay was done six times. Data were expressed as a per-
centage of control. The statistical signiﬁcance of the data was
analyzed by Student’s t-test.
Results
Correlation of HIF-2a Stability and Cytoskeletal
Integrity in the Human Placenta
We previously demonstrated that MAP2K1/2-dependent
HIF-2 activity regulates LIMK1 expression and cytoskeletal
integrity in mouse TSCs differentiated along the invasive
lineage.54 The active (phosphorylated) form of theMAP2K1/2
target MAPK3/1 was identiﬁed in villous cytotrophoblasts
(vCTBs) underlying SynTs before cell fusion, as well as in
invasive CTBs (iCTBs) within mid-second trimester (19
weeks) human placentas (Supplemental Figure S2, A and B).
Multinucleated SynTs surrounding chorionic villi, however,
failed to stain for pMAPK3/1, suggesting that this pathway
was differentially regulated during trophoblast differentiation.
We also assessed cytoskeletal integrity in the same structures
and noted that although vCTBs and invasive CTBs exhibited
robust microtubule networks, SynTs did not. Speciﬁcally, a-
tubulin staining was reduced in these cells, compared with all
other cell types that comprise the placenta (Supplemental
Figure S2, C and D). Similar results were obtained with
ﬂuorescein isothiocyanateephalloidin staining (not
shown), indicating disruption of the actin as well as the
microtubule cytoskeleton on SynT formation. To more
carefully delineate HIF-2a expression and localization
during human placental development, and correlate its
expression with cytoskeletal integrity, we analyzed ﬁrst and
second trimester human placentas from three different
gestational ages. First, we investigated ﬁrst trimester
ﬂoating villi (FV) and noted that although the vCTB pro-
genitors of multinucleated SynTs stained strongly for HIF-
2a and a-tubulin, SynT formation was associated with near
complete absence of HIF-2a as well as a-tubulin immu-
noreactivity (Figure 2). In AV, ﬁrst and second trimester
human placentas exhibited nuclear immunoreactivity for
HIF-2a within cell columns. These same structures simi-
larly stained strongly for a-tubulin. By the beginning of the
third trimester, levels of HIF-2a were generally reduced,
and we noted a more diffuse cytoplasmic as well as nuclear
localization pattern, similar to what has been described in
differentiated mouse TSCs.40
Developmental Regulation of LIMK1 Expression in the
Human Placenta
To determine whether LIMK1 was similarly expressed in the
human placenta in regions also known to contain stable
HIF-2a, we performed serial immunoﬂuorescence micro-
scopyebased analyses of human placental samples duringThe American Journal of Pathology - ajp.amjpathol.orgthe ﬁrst two trimesters of gestation. cCTBs within AVs,
previously shown to contain high levels of HIF-2a60 and
veriﬁed by us (see above), also expressed LIMK1 during this
time period (Figure 3). Invasive CTBs also expressed
LIMK1, albeit to slightly lower levels (Figure 3). In FV
(Figure 4); however, LIMK1 was expressed at generally
lower levels, with reductions in LIMK1 expression noted
speciﬁcally within the SynT layer (Figure 4). Importantly,
this is the layer in which MAP2K1/2 activity and HIF-2a
stability are also diminished. These results are consistent
with the observed disruption in the cytoskeleton following
cell fusion and suggest potential roles for HIF-2edependent
LIMK1 expression in promoting CTB differentiation away
from SynT and toward iCTB/EVTs. Importantly, however,
the regulation of HIF transcriptional activity is complex and
not simply dependent on protein stability. For example, the
extent of HIF-2a acetylation can regulate its activity.633325
Figure 4 Expression pattern of LIMK1 within ﬂoating villi (FV) during
the ﬁrst two trimesters of human placental development. Immunoﬂuores-
cence microscopy-based analysis of LIMK1 expression was undertaken in
tissue sections of human segments containing FV at weeks 6, 9, 15, and 23.
CK staining served as a marker of placental cells. Maternal uterine struc-
tures do not exhibit CK immunoreactivity. DAPI was used to stain nuclei.
vCTBs and SynTs are indicated.
Zhou et alAcetyl transferase or deacetylase activity can be regulated by
various environmental conditions such as oxygen or nutrient
deprivation to affect transcription factor activity or stabil-
ity.64 We therefore additionally tested whether inhibition of
class I/II histone deacetylase (HDAC) activity with sodium
butyrate or class III activity with sirtinol could modulate
HIF-2 activity/stability in the placenta. HIF-2 expression in
Hif-1/2a/ TSCs promotes LIMK1 protein accumulation,
which is inhibited by both classes of HDAC inhibitors
(Supplemental Figure S3). Interestingly, however, whereas
sodium butyrate resulted in HIF-2a protein destabilization
and subsequent LIMK1 down-regulation, class III HDAC
inhibition with sirtinol only resulted in impaired HIF-2
transcriptional activity without affecting its stability. These
results indicate that HIF-2edependent LIMK1 expression
can be regulated by more than just HIF-2 protein stabilization
and can be subjected to environmental stress-induced inputs
mediated by diverse HDAC family members.3326LIMK1 Activity Regulates Human CTB Cytoskeletal
Integrity, Invasion, MMP Processing, and
Differentiation in Vitro
To test the role of LIMK1 activity in CTBs, we cultured
primary human CTBs in vitro in the presence of the speciﬁc
LIMK1 inhibitor BMS-559,65 using a standard concentration
(10 mmol/L) developed to detail the role of LIMK1 in cancer
cell migration. LIMK1 inhibition resulted in dramatic alter-
ations of the CTB cytoarchitecture in vitro (Figure 5A).
Although control CTBs isolated from second trimester
human placentas and cultured in vitro frequently exhibited
robust actin stress ﬁbers as evidenced by anti-actin staining,
CTBs treated with BMS-5 did not. They continued to
maintain a rounded shape with a complete absence of actin
stress ﬁbers (Figure 5A). Importantly, BMS-5etreated CTBs
did not show evidence of increased apoptosis when
compared with vehicle-treated controls (Supplemental
Figure S4), indicating that these results were not due to
drug toxicity. To conﬁrm that BMS-5 treatment resulted in
LIMK1 inhibition, we performed immunoblot-based analysis
of LIMK1, as well as of its target coﬁlin. BMS-5 triggered
noticeable decreases in coﬁlin phosphorylation (Figure 5B).
Interestingly, total LIMK1 levels were also reduced
following LIMK inhibition. LIMK1 expression is reduced in
SynTs compared with iCTBs, suggesting that LIMK1 inhi-
bition promotes differentiation along the SynT lineage.
Further, suggesting an inhibition of differentiation along the
iCTB lineage in vitro, LIMK inhibition also increased
expression of the SynT marker PAPP-A in cultured CTBs
(Figure 5, C and D). Next, we assessed whether LIMK1 in-
hibition could functionally impair CTB invasion through
Matrigel. BMS-5 inhibited ﬁrst trimester (10 weeks), as well
as late second trimester (23 weeks) (Supplemental
Figure S5), CTB invasion in vitro (Figure 5E). Finally, and
consistent with reports that LIMK activity can regulate MMP
secretion, LIMK inhibition with BMS-5 impaired MMP-9
secretion by CTBs maintained in vitro, without affecting
MMP-9 expression (Figure 5F). Collectively, these results
indicate that LIMK inhibition in vitro impairs CTB differ-
entiation along the invasive lineage while disrupting cyto-
skeletal integrity and inhibiting MMP processing.
Importantly, CTB invasion, differentiation, as well as MMP
processing, are frequently impaired in the PE setting in vivo.
LIMK1 Levels Are Frequently Decreased in the Setting
of Severe PE in Vivo
To test whether LIMK1 levels may be diminished in the pla-
centas of women suffering from PE, we isolated placentas from
women diagnosed with severe PE and compared their expres-
sion of LIMK1 with age-matched control placentas obtained
from women without PE but who delivered prematurely due to
preterm labor without overt clinical signs and symptoms of
infection. iCTBs in severe PE placentas were frequently char-
acterized by diminished LIMK1 immunoreactivity whenajp.amjpathol.org - The American Journal of Pathology
Figure 5 LIMK inhibition blocks CTB invasion and differentiation in vitro. A: Primary human CTBs were stained with an antibody speciﬁc for a-actin (green)
following culture without or with 10 mmol/L BMS-5 (top left panel and top right panel). CTBs frequently exhibit robust actin cytoskeletons when cultured
in vitro (top left panel and top right panel), which are completely lost in the presence of LIMK-inhibitor, BMS-5 (bottom left panel and bottom right panel).
B: LIMK inhibition blocks LIMK signaling. Immunoblot (IB) analysis of LIMK1 activity with (þ) or without () 10 mmol/L LIMK inhibitor BMS-5. BMS-5 reduces
coﬁlin phosphorylation and decreases LIMK expression, suggesting an association between LIMK activity and CTB differentiation along the iCTB lineage. C:
Immunoblot analysis of PAPP-A expression in human CTBs differentiated in vitro without and with BMS-5. LIMK inhibition promotes expression of the SynT
marker PAPP-A in differentiating human CTBs in vitro. D: Immunoﬂuorescence microscopy-based analysis of LIMK expression in the second trimester (TM)
ﬂoating villous. Note the robust expression in the overlying SynT layer. E: CTB invasion assay. BMS-5 impaired the invasion of CTBs derived from ﬁrst trimester
(10 weeks) placenta in a Matrigel-based invasion assay. F: LIMK expression impairs MMP-9 secretion by human CTBs cultured in vitro. Immunoblot assay of
secreted MMP-9 in CTB cultured media (CTB-CM) versus CTB whole-cell lysate (CTB-lysate) using an MMP-9-speciﬁc antibody. As seen, LIMK-inhibition with
BMS-5 does not impair MMP-9 production, but it impairs its secretion into media. Ponceau S staining of total protein content in each sample indicates
equivalent loading within groups. **P < 0.01. DMSO, dimethyl sulfoxide; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; IB, immunoblot.
LIMK1 Regulates Human Placentationcompared with gestational ageematched controls (Figure 6A).
Additionally, we performed direct comparisons of LIMK1
protein levels via immunoblotting using primary CTBs isolated
from control preterm labor and severe PE placentas. CTB ly-
sates obtained from placentas with PE frequently exhibited
reduced levels of LIMK1 compared with control placentas
(Figure 6B). Densitometric analysis of expression levels
conﬁrmed these ﬁndings (Figure 6C).Discussion
Our results suggest a potentially novel mechanism whereby
HIF activity may contribute to human placental development as
well as PE pathogenesis. We previously demonstrated that HIF
activity is critical for placentation in the mouse.39e41 In its
absence, altered trophoblast differentiation results in a grossly
disrupted placental architecture and impaired formation of a
maternalefetal vascular exchange interface. Interestingly,The American Journal of Pathology - ajp.amjpathol.orgalthough the deﬁciency of HIF-1a or -2a alone is insufﬁcient to
signiﬁcantly compromise mouse placental development, com-
bined deﬁciency of both subunits, or the absence of their
requisite heterodimerization partner ARNT/HIF-1b, is sufﬁ-
cient. These results helped establish a critical role for HIF ac-
tivity during placental development. More recently, we
demonstrated an additional level of complexity with respect to
HIF-dependent gene expression in the placenta. We showed
that similar to what has been described in the developing ner-
vous system inmice,66 and during hematopoiesis inDrosophila
melanogaster,67 the HIF family of transcription factors can act
via noncanonical means to activate downstream target gene
expression to drive development in the mouse placenta. Spe-
ciﬁcally, we showed that the LIMK1 gene can be regulated by
HIF-2a via its ability to interact with and activate MYC (alias
c-MYCe)dependent transcription in mouse TSCs.54 Similar
roles for HIF-2a have been shown to be operative in multiple
human malignancies68 and highlight potential points of diver-
gence between HIF-1ae and -2aedependent activities. Here,3327
Figure 6 LIMK1 expression is decreased in the preeclampsia setting in
utero. Early third trimester human placental samples obtained from women
diagnosed with severe preeclampsia (sPE) were compared with placental
samples obtained from gestational age matched samples obtained from
women who delivered due to normal preterm labor (nPTL) without overt
signs of clinical infection. A: Immunoﬂuorescence microscopy-based ap-
proaches indicate that although invasive CTBs and cCTBs in nPTL placentas
exhibit robust LIMK1 immunoreactivity, the expression of LIMK1 is
frequently decreased in the sPE setting in vivo. B: Immunoblot analysis of
CTB lysates derived from additional nPTL and sPE placentas. C: Densito-
metric analysis of relative expression levels of LIMK1 in B.
Figure 7 Schematic representation of LIMK1 activity in the human
placenta. During normal pregnancy, CTB progenitors of invasive extravillous
trophoblasts express high levels of LIMK1 likely driven by HIF-2a activity.
LIMK1 promotes cytoskeletal integrity as well as MMP processing, thereby
promoting CTB invasion. CTB invasion and differentiation are linked.
Therefore, LIMK1 activity also enhances CTB differentiation while inhibiting
SynT formation. In the setting of preeclampsia, LIMK1 expression is
frequently diminished, resulting in altered CTB cytoskeletal integrity, MMP
processing, differentiation and invasive capacity. This may contribute to
shallow placentation with associated impaired spiral artery remodeling and
imbalances in maternal blood pressure regulation. PreE, preeclampsia.
Zhou et alwe provide evidence that this pathway is conserved during
human placental development and that LIMK1 activity pro-
motes human CTB differentiation and invasion. Importantly,
this pathway appears to be impaired in the setting of PE and
may contribute to its etiology.
An additional surprising ﬁnding has been that factors other
than oxygen tension can regulate HIF stability in the
placenta. We previously demonstrated that trophoblast ECM
composition can trigger HIF-1a and -2a subunit accumula-
tion as a function of differentiation.54 In mouse TSCs derived
on a bed of feeder cells, growth factor withdrawal induced
differentiation results in robust HIF-1a and -2a stabilization
and transcriptional activity independent of oxygen tension
that is required during invasive trophoblast giant cell for-
mation. Altering the ECMonwhich TSCs are cultured blocks
this differentiation-dependent HIF induction. This has rele-
vance for placentation because in concert with phenotypic
alterations in invasive trophoblasts, the uterine ECM is
remodeled to promote successful implantation and tropho-
blast invasion.11,69e71 This process is enhanced by tropho-
blast expressed MMPsda family of enzymes that break
down ECM components.72 In this capacity, multiple studies3328have highlighted the role of these proteases in regulating
trophoblast invasion,73e88 and MMP9 deﬁciency in pregnant
mice triggers clinical diagnostic features of PE.89 Interest-
ingly, in addition to its well-known role regulating the
cytoskeleton through coﬁlin56 and p2590 phosphorylation,
LIMK1 also regulates MMP processing.91 Here, we show
that LIMK1 plays similar roles in human CTBs and likely
contributes to its ability to promote CTB invasion. Further-
more, its expression pattern in the human placenta mirrors
what we described in mouse TSCs. Coupled with our ob-
servations that ECM composition can trigger differentiation-
dependent HIF induction54 and that HIF activity can regulate
TSC cell surface integrin localization,44 these results suggest
the existence of a positive feedback loop wherein ECM
composition, HIF activity, and cell surface integrin expres-
sion collectively promote the invasive phenotype in tropho-
blasts. We suggest that HIF-2edependent LIMK1 expression
represents one mechanism that helps propel this process by
modulating CTB MMP secretion and cytoskeletal integrity.
Cytoskeletal rearrangement is central to trophoblast dif-
ferentiation.57 For example, calponin 3emediated actin
cytoskeletal rearrangement promotes SynT fusion,58 whereas
caspases help remodel the fodrin cytoskeleton during this
process,92 and stathmin, a microtubule regulatory protein, is
associated with invasive trophoblast migration.93 In TSCs,
microtubule or actin cytoskeleton disruption triggers SynT
formation in conditions that would otherwise result in
trophoblast giant cell formation.54 Interestingly, HIF stability
can also be modulated by cytoskeletal integrity,52,94 sug-
gesting yet another feed-forward mechanism during invasiveajp.amjpathol.org - The American Journal of Pathology
LIMK1 Regulates Human Placentationtrophoblast differentiation wherein HIF activity can promote
cytoskeletal stability that, in turn, helps sustain HIF activity.
Multiple studies have investigated an association between
HIF function and PE pathogenesis.7,45,46,95,96 Here, we show
that LIMK1 expression is frequently diminished in the severe
PE setting in utero, and thus may contribute to the impaired
trophoblast differentiation, invasion, and endovascular
remodeling associated with this disease process, likely
downstream of blunted HIF-2 activity (Figure 7). LIMK1
expression is highest within the cell column, along with HIF-
2a, before iCTB migration. This may reﬂect the dual role of
LIMK1 in the placenta: preventing SynT formation while
promoting CTB invasion. Given that cytoskeletal rear-
rangement is central to both cell fusion as well as cell inva-
sion, this seems reasonable. Once invasion has been initiated,
perhaps other mechanisms take on a more pivotal role for
maintaining invasion. Interestingly, LIMK1 activity has been
shown to be important for the initiation of tumor cell inva-
sion,59 consistent with our observations. In addition to hyp-
oxia, alterations in placental ECM composition can modulate
HIF activity and thereby direct trophoblast invasion and fate,
and may actually be the prime driver of HIF activity in the
placenta. It is therefore important that the presence of HIF
activity not be used as the sole marker of tissue hypoxia
in vivo. Additionally, post-translational modiﬁcation of HIF-
a subunits, including but not limited to acetylation, dramat-
ically impact its activity and can be regulated by multiple
inputs, including nutrient availability and redox state.63
Given that hypoxia, redox stress, altered ECM remodeling,
and bioenergetic compromise have all been associated with
PE pathogenesis, our efforts to build a more thorough picture
of the role of HIF-dependent gene expression during
placental development should yield novel insights into the
etiology of this enigmatic pregnancy complication.
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